Evidence map›Paper›PMID 33896823›Full record

ArticleCancer biomarkers : section A of Disease markers2021

Three plasma-based microRNAs as potent diagnostic biomarkers for endometrial cancer.

Xingchen Fan, Minmin Cao, Cheng Liu, Cheng Zhang, Chunyu Li, Wenfang Cheng, Shiyu Zhang, Huo Zhang, Wei Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xingchen FanDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Minmin CaoDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Cheng LiuDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Cheng ZhangDepartment of Science and Technology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Chunyu LiDepartment of Intensive Care Unit, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wenfang ChengDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Shiyu ZhangDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Huo ZhangDepartment of Medical Oncology, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
Wei ZhuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs), with noticeable stability and unique expression pattern in plasma of patients with various diseases, are powerful non-invasive biomarkers for cancer detection including endometrial cancer (EC).

objectiveThe objective of this study was to identify promising miRNA biomarkers in plasma to assist the clinical screening of EC.

methodsA total of 93 EC and 79 normal control (NC) plasma samples were analyzed using Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) in this four-stage experiment. The receiver operating characteristic curve (ROC) analysis was conducted to evaluate the diagnostic value. Additionally, the expression features of the identified miRNAs were further explored in tissues and plasma exosomes samples.

resultsThe expression of miR-142-3p, miR-146a-5p, and miR-151a-5p was significantly overexpressed in the plasma of EC patients compared with NCs. Areas under the ROC curve of the 3-miRNA signature were 0.729, 0.751, and 0.789 for the training, testing, and external validation phases, respectively. The diagnostic performance of the identified signature proved to be stable in the three public datasets and superior to the other miRNA biomarkers in EC diagnosis. Moreover, the expression of miR-151a-5p was significantly elevated in EC plasma exosomes.

conclusionsA signature consisting of 3 plasma miRNAs was identified and showed potential for the non-invasive diagnosis of EC.

Indexed as

Biomarkers, TumorEndometrial NeoplasmsFemaleHumansMicroRNAsMiddle AgedBiomarkers, TumorMicroRNAsdiagnostic biomarkerendometrial carcinomaPlasma microRNAqRT-PCR

Identifiers

PMID33896823
PMCPMC12500017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.